Quick summary
Hexarelin is the most potent GHRP, producing up to 7x baseline GH spikes via the ghrelin receptor. Beyond GH release, it has notable cardioprotective properties acting directly on cardiac tissue, and was studied in Phase II heart failure trials.
Overview
Hexarelin is one of the most potent synthetic growth hormone releasing peptides (GHRPs), producing the strongest GH release of any GHRP. It is a hexapeptide analog of GHRP-6 with a methylated tryptophan residue that increases its potency. Beyond GH release, hexarelin has notable cardioprotective properties, acting directly on cardiac tissue independent of GH. It was studied in clinical trials for heart failure.
Mechanism of action
Hexarelin binds to the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, stimulating robust GH release. It produces the highest GH spike of any GHRP (up to 7x baseline). It also activates cardiac GHS receptors (GHS-R1a in cardiomyocytes), providing direct cardioprotection: reducing cardiac fibrosis, improving ventricular function, and protecting against ischemia-reperfusion injury. Unlike Ipamorelin, hexarelin does increase cortisol and prolactin at higher doses.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| GH release / body composition | subcutaneous | 100–200 mcg | 2-3x daily | Inject on empty stomach. GH response desensitizes with continuous use — cycle 4-8 weeks on, 4 weeks off. Keep doses moderate to limit cortisol/prolactin effects. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Clinical studies confirm potent GH release (5-7x baseline) with dose-dependent response. Phase II heart failure trials showed improved cardiac function (increased LVEF, reduced wall stress) independent of GH effects. Cardioprotective effects demonstrated in post-MI patients and animal models. GH response attenuates with chronic use (desensitization of GHS-R1a), recommending cyclic use. Side effects include increased cortisol and prolactin at doses above 2mcg/kg, appetite stimulation, and water retention.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Hexarelin for synergistic effects.
Legal status
Not FDA-approved. Was in clinical development for heart failure (Europeptides). Available as a research peptide. Not scheduled.
Sourcing & access
Research compound
Hexarelin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Hexarelin (Examorelin) is a synthetic hexapeptide growth hormone releasing peptide and one of the most potent GHRPs available. It produces the strongest GH release of any GHRP and has unique cardioprotective effects independent of growth hormone.
Hexarelin produces higher GH spikes (up to 7x baseline vs 3-5x for Ipamorelin) but also increases cortisol and prolactin at higher doses. Ipamorelin is considered cleaner with fewer side effects, while Hexarelin is chosen for maximum GH output and cardiac benefits.
Yes, Phase II heart failure trials showed Hexarelin improved cardiac function by increasing left ventricular ejection fraction and reducing wall stress. These cardioprotective effects are mediated through direct activation of GHS receptors on cardiomyocytes, independent of GH.
Yes, GH response attenuates with continuous use due to desensitization of the GHS-R1a receptor. Cyclic use of 4 to 8 weeks on, followed by 4 weeks off, is recommended to maintain effectiveness.
Common protocols use 100 to 200 mcg injected subcutaneously 2 to 3 times daily on an empty stomach. Keeping doses moderate helps limit the dose-dependent cortisol and prolactin elevation seen above 2 mcg per kg. Cycling 4 to 8 weeks on followed by 4 weeks off helps avoid GHS-R1a desensitization.
Research references
- The cardiovascular action of hexarelinPubMed
- Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgeryPubMed
- The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling PathwayPubMed
- Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the ratPubMed
- The Safety and Efficacy of Growth Hormone SecretagoguesPubMed